Video
Update on adjuvant treatment of bladder cancer
Author(s):
“The bar is high; we want to be curing these patients, not just delaying a recurrence of their cancer,” says Arlene O. Siefker-Radtke, MD.
Video Player is loading.
In this video, Arlene O. Siefker-Radtke, MD, discusses recent developments in the adjuvant treatment of bladder cancer. Siefker-Radtke is a professor of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston. She was interviewed at the 2022 LUGPA Annual Meeting in Chicago, Illinois.
Related Videos
Andrew Armstrong, MD, previews key prostate cancer data at ASCO 2025
5 key trial insights from AUA 2025
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Alexander Glaser, MD, on real-world outcomes with Aquablation
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Margaret Knoedler, MD, on Ho:YAG vs thulium fiber laser for ureteroscopy
Related Content
